Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

227
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
227
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

185
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
185
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

181
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
181
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

170
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
170

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

PANA-Surv: A Pathway-Guided Adaptive Neighborhood Augmentation Framework Using KEGG Pathways for Multi-Omics Cancer Prognosis.

Genes·2026
Same author

Large scale plasma proteomics: opening up new frontiers of biomarker and therapeutic target discoveries in COPD.

The European respiratory journal·2026
Same author

Bayesian adaptive design for clinical trials with potential subgroup effects.

Statistical methods in medical research·2026
Same author

A Bayesian Multilevel Joint Modeling of Longitudinal and Survival Outcomes in Cluster Randomized Controlled Trial Studies.

Statistics in medicine·2026
Same author

Evaluating the Effectiveness of a Family-Based Lifestyle Intervention for Managing Childhood Overweight: Protocol for a Randomized Controlled Trial.

JMIR research protocols·2025
Same author

scSorterDL: a deep neural network-enhanced ensemble LDAs for single cell classifications.

Briefings in bioinformatics·2025

相关实验视频

Updated: Jan 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

调整适应性2/3期设计与剂量优化中的不一致性

Cong Chen1, Mo Huang2, Xuekui Zhang3

  • 1Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.

Pharmaceutical statistics
|September 26, 2025
PubMed
概括

在瘤药物开发中的适应性2/3期设计可以通过解决剂量选择不一致性来改进. 本研究引入了统计方法,以平衡监管需求,赞助商利益和实际药物开发挑战.

关键词:
适应性设计是适应性的设计.剂量优化剂量优化不一致性 不一致性 不一致性第二阶段和第三阶段的试验.无设计 无设计我类型的错误控制控制.

更多相关视频

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

相关实验视频

Last Updated: Jan 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

科学领域:

  • 临床试验方法论 临床试验方法论
  • 瘤学 药物开发 药物开发
  • 生物统计学 生物统计学

背景情况:

  • 适应性2/3期设计对于瘤药物开发至关重要,因为1期数据有限.
  • 鉴定最佳剂量是具有挑战性的,因为早期阶段的数据不足.
  • 第二阶段和第三阶段结果之间的不一致性造成了监管和实际障碍.

研究的目的:

  • 开发适应性2/3期设计的统计方法,明确解决剂量选择不一致的问题.
  • 在适应性试验设计中平衡监管谨慎,赞助商利益和实际考虑.
  • 为了考虑剂量优化中"挑选赢家"的概率.

主要方法:

  • 将不一致性问题纳入统计分析.
  • 一个不一致的切断界限的规范.
  • 使用三种假设测试策略:保守,侵略和中立.
  • 考虑到"挑选赢家"的概率.

主要成果:

  • 拟议的方法为管理适应性2/3期设计中的剂量选择缺陷提供了一个框架.
  • 证明了在适应性试验设计中平衡竞争利益的方法.
  • 强调积极处理潜在的不一致性的重要性.

结论:

  • 统计策略提高了瘤学适应性2/3期设计的可靠性.
  • 这种方法为药物开发中的剂量优化提供了更强大的方法.
  • 在这种适应性试验设计的未经探索的领域中,需要进一步的研究.